GnRH-analogues for ovarian protection in childhood cancer patients

How adult hypotheses are relevant in Prepubertal females

Shelby E. Osborne, Laura Detti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Systemic chemotherapy frequently causes primary ovarian insufficiency. In prepubertal girls, currently the only option to preserve ovarian function is ovarian tissue preservation. The use of gonadotropin-releasing hormone analogues given in combination with chemotherapy has been studied in reproductive age women. The exact mechanism is unknown, but some of the proposed protective mechanisms could theoretically protect the prepubertal ovary as it has been theorized in many of the studies on reproductive age women. None of the studies implies an adverse affect of GnRH analogue administration in terms of worsening health or cancer status. As 83% of children diagnosed with cancer will survive into adulthood, GnRH analogue administration to female childhood cancer patients in combination with chemotherapy might represent a valuable attempt to preserve future ovarian function and fertility when ovarian tissue preservation is not an option.

Original languageEnglish (US)
Pages (from-to)856-863
Number of pages8
JournalCurrent Drug Targets
Volume14
Issue number8
DOIs
StatePublished - Aug 15 2013

Fingerprint

Chemotherapy
Gonadotropin-Releasing Hormone
Tissue Preservation
Combination Drug Therapy
Tissue
Primary Ovarian Insufficiency
Neoplasms
Fertility
Ovary
Health
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

GnRH-analogues for ovarian protection in childhood cancer patients : How adult hypotheses are relevant in Prepubertal females. / Osborne, Shelby E.; Detti, Laura.

In: Current Drug Targets, Vol. 14, No. 8, 15.08.2013, p. 856-863.

Research output: Contribution to journalArticle

@article{4156aa4109d34f7e8c564b379827173f,
title = "GnRH-analogues for ovarian protection in childhood cancer patients: How adult hypotheses are relevant in Prepubertal females",
abstract = "Systemic chemotherapy frequently causes primary ovarian insufficiency. In prepubertal girls, currently the only option to preserve ovarian function is ovarian tissue preservation. The use of gonadotropin-releasing hormone analogues given in combination with chemotherapy has been studied in reproductive age women. The exact mechanism is unknown, but some of the proposed protective mechanisms could theoretically protect the prepubertal ovary as it has been theorized in many of the studies on reproductive age women. None of the studies implies an adverse affect of GnRH analogue administration in terms of worsening health or cancer status. As 83{\%} of children diagnosed with cancer will survive into adulthood, GnRH analogue administration to female childhood cancer patients in combination with chemotherapy might represent a valuable attempt to preserve future ovarian function and fertility when ovarian tissue preservation is not an option.",
author = "Osborne, {Shelby E.} and Laura Detti",
year = "2013",
month = "8",
day = "15",
doi = "10.2174/1389450111314080005",
language = "English (US)",
volume = "14",
pages = "856--863",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - GnRH-analogues for ovarian protection in childhood cancer patients

T2 - How adult hypotheses are relevant in Prepubertal females

AU - Osborne, Shelby E.

AU - Detti, Laura

PY - 2013/8/15

Y1 - 2013/8/15

N2 - Systemic chemotherapy frequently causes primary ovarian insufficiency. In prepubertal girls, currently the only option to preserve ovarian function is ovarian tissue preservation. The use of gonadotropin-releasing hormone analogues given in combination with chemotherapy has been studied in reproductive age women. The exact mechanism is unknown, but some of the proposed protective mechanisms could theoretically protect the prepubertal ovary as it has been theorized in many of the studies on reproductive age women. None of the studies implies an adverse affect of GnRH analogue administration in terms of worsening health or cancer status. As 83% of children diagnosed with cancer will survive into adulthood, GnRH analogue administration to female childhood cancer patients in combination with chemotherapy might represent a valuable attempt to preserve future ovarian function and fertility when ovarian tissue preservation is not an option.

AB - Systemic chemotherapy frequently causes primary ovarian insufficiency. In prepubertal girls, currently the only option to preserve ovarian function is ovarian tissue preservation. The use of gonadotropin-releasing hormone analogues given in combination with chemotherapy has been studied in reproductive age women. The exact mechanism is unknown, but some of the proposed protective mechanisms could theoretically protect the prepubertal ovary as it has been theorized in many of the studies on reproductive age women. None of the studies implies an adverse affect of GnRH analogue administration in terms of worsening health or cancer status. As 83% of children diagnosed with cancer will survive into adulthood, GnRH analogue administration to female childhood cancer patients in combination with chemotherapy might represent a valuable attempt to preserve future ovarian function and fertility when ovarian tissue preservation is not an option.

UR - http://www.scopus.com/inward/record.url?scp=84881361063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881361063&partnerID=8YFLogxK

U2 - 10.2174/1389450111314080005

DO - 10.2174/1389450111314080005

M3 - Article

VL - 14

SP - 856

EP - 863

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 8

ER -